ArticleCureus2020
Alexandrite Laser-Induced Choroidal Neovascularization Successfully Treated With Aflibercept.
Article in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Article
- A customized regimen of intravitreal aflibercept for the treatment of choroidal neovascularization secondary to different chorioretinal diseases.International journal of retina and vitreous · 2023Article
- Aflibercept treatment for delayed retinotomy-associated choroidal neovascularization: A case report and literature review.Taiwan journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 33-year-old female was referred to the ophthalmology department after an accidental eye injury to her right eye during a hair removal session using alexandrite laser. Although she initially experienced no symptoms, when re-examined one and a half months later the best-corrected visual acuity (BCVA) of the affected eye was 20/40 secondary to choroidal neovascularization confirmed by fluorescein angiography (FA) and optical coherence tomography (OCT). Intravitreal anti-vascular endothelial growth factor (VEGF) therapy (three monthly injections of aflibercept) led to complete regression of the neovascularization and functional recovery which was maintained at one-year follow-up post original injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.